Neuroleptika minimal

Volkmar Aderhold

doi:10.1055/s-0041-102180

PiD - Psychotherapie im Dialog, Inhaltsverzeichnis

PiD - Psychotherapie im Dialog 2015; 16(03): 75-80
DOI: 10.1055/s-0041-102180

Aus der Praxis

Neuroleptika minimal

Dosisabhängige Risiken der medikamentösen Therapie bei Psychosen

Volkmar Aderhold

Abstract

Neuroleptika wirken nicht kurativ. Neben somatischen und hormonalen Nebenwirkungen werden ihre neurotoxischen Effekte immer offensichtlicher. Daher gilt für sie nicht die oft suggerierte Alltagslogik des „mehr hilft mehr“, sondern ein „weniger ist mehr“.

Volltext

Referenzen

Literatur
Aderhold V, Weinmann S, Hägele C, Heinz A. Frontale Hirnvolumenminderung durch Antipsychotika?. Nervenarzt 2015; 86: 302-323 im Internet http://link.springer.com/article/10.1007/s00115-014-4027-5
American Psychiatric Association Im Internet http://www.choosingwisely.org/wp-content/uploads/2015/02/APA-Choosing-Wisely-List.pdf
Carpenter Jr WT, Buchanan RW, Kirkpatrick B, Breier AF. Diazepam treatment of early signs of exacerbation in schizophrenia. Am J Psychiatry 1999; 156: 299-303
Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004; 24: 192-208
De Hert M, Cohen D, Bobes J et al Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011; 10: 138-151
Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) Leitlinien Schizophrenie. letzte Überarbeitung Nov 2005
Essock SM, Schooler NR, Stroup TS et al. Schizophrenia Trials Network. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 2011; 168: 702-708
Fusar-Poli P, Smieskova R, Kempton MJ et al. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev 2013; 37: 1680-1691
Ginovart N, Wilson AA, Hussey D, Houle S, Kapur S. D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacology 2009; 34: 662-671
Götzsche P. Deadly medicines and organized crime. How big pharma has corrupted healthcare. New York: Radcliffe: 2013
Harrow M, Jobe TH, Faull RN. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychol Med 2012; 42: 2145-2155
Hori H, Yoshimura R, Katsuki A et al. Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients. J Psychiatr Res 2013; 47: 1843-1848
Husa AP et al. Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia—An observational 9-year follow-up study. Schizophrenia Research 2014; 158: 134-141
Lepping P, Sambhi RS, Whittington R et al. Clinical relevance of findings in trials of antipsychotics: systematic review. Br J Psychiatry 2011; 198: 341-345
Leucht S, Arbter D, Engel RR et al. How effective are second-generation antipsychotic drugs?. Molecular Psychiatry 2009; 14: 429-447
Levine SZ, Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophr Bull 2010; 36: 624-632
Levine SZ, Rabinowitz J, Faries D et al. Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial. Schizophr Res 2012; 137: 141-146
Radua J, Borgwardt S, Crescini A et al. Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication. Neuroscience and Biobehavioral Reviews. Neurosci Biobehav 2012; 36: 2325-2333
Samaha A-N. Can antipsychotic treatment contribute to drug addiction in schizophrenia?. Prog Neuropsychopharmacol Biol Psychiatry 2014; 52: 9-16
Samaha AN, Reckless GE, Seeman P et al. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry 2008; 64: 145-152
Seeman P, Weinshenker D, Quirion R et al. Dopamine supersensitivity correlates with D2 High states, implying many paths to psychosis. Proc Natl Acad Sci U S A 2005; 102: 3513-3518
Seeman P, Schwarz J, Chen JF et al. Psychosis pathways converge via D2 high dopamine receptors. Synapse 2006; 60: 319-346
Seeman P. All roads to schizophrenia lead to dopamine supersensitivity and elevated Dopamine D2High receptors. CNS Neurosci Ther 2011; 17: 118-132
Suzuki T, Uchida H, Tanaka KF et al. Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. Int Clin Psychopharmacol 2003; 18: 323-329
Suzuki T, Uchida H, Tanaka KF et al. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol 2004; 7: 133-142
Wunderink L, Nieboer RM, Wiersma D et al. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 2013; 70: 913-920
Wunderink L, Nienhuis FJ, Sytema S et al. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 2007; 68: 654-661